COIOSDeep risk insights through multi-disciplinary research across the globe
African American man at a cash register in a Sears department store
Item new Peer-reviewed Added

Consistent glucose monitor users stayed on GLP-1 drugs longer in type 2 diabetes

In US claims for adults with type 2 diabetes starting a GLP-1 drug, 68.4% of consistent glucose monitor users were still on it at one year, against 51.9% of non-users.

US claims matched 934 adults with type 2 diabetes using a glucose monitor on 80% or more days to 3,747 non-users starting a GLP-1 drug. At one year, 68.4% of monitor users were still on the drug as compared to 51.9% of non-users. The adjusted hazard ratio for stopping was 0.56, with matching on age, sex, ethnicity, therapy, comorbidity and insurance.

Why it is interesting: Monitor use tracks with persistence on GLP-1 drugs, where about half of non-users had stopped within a year.

Source
Diabetes Technology & Therapeutics, 19 September 2026
Paper
Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study
Authors
Wright EE, Huang E, Bindal A
DOI
10.1177/15209156261489904
Type
Peer-reviewed article
Design
Retrospective matched-cohort study of US administrative claims (Inovalon Insights), 934 adherent CGM users matched to 3,747 non-users with type 2 diabetes starting a GLP-1 receptor agonist, 2017-2024
Verdict
New finding
Driver
Obesity, diabetes and GLP-1
Free full text
Free to read at the publisher

Other drivers in Health today